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Renal cell carcinoma is known to be mostly chemotherapy-resis-
tant (Hrusshesky and Murphy, 1977; Duensing et al, 1994; Yagoda
et al, 1995). While the prognosis of patients with metastatic renal
cell carcinoma remains poor, objective and durable remissions can
be reached in approximately one third of patients using palliative
biochemotherapies, especially employing combined cytokines and
5-fluorouracil (Lopez et al, 1996; Ellerhorst et al, 1997).
Capecitabine is an orally administered fluoropyrimidine carba-
mate, activated by a three-step conversation process to the cyto-
toxic agent 5-FU. After oral administration, capecitabine is first
metabolized in the liver to 5′ -DFCR. Second, 5′ -DFCR is
converted to 5′ -DFUR by cytidine deaminase, located in high
concentrations in the liver and tumour tissues (Takebayashi et al,
1996; Miwa et al, 1998). Finally, conversation of 5′ -DFUR to 5-
FU occurs by thymidine phosphorylase, which is present at higher
concentrations in tumour than in normal tissue, thus minimizing
the exposure of healthy body tissues to 5-FU (Takebayashi et al,
1996; Ishikawa et al, 1998a; 1998b). The efficacy and favourable
safety profiles of capecitabine have been demonstrated in patients
with common solid tumours such as colorectal and breast cancer
(Blum et al, 1999; Mackean et al, 1998; Schüller et al, 1997). So
far, no results have been reported in advanced renal carcinoma.
Here we report a phase II clinical trial of p.o. capecitabine
combined with s.c. interferon-α 2a, s.c. interleukin-2 and p.o. 13-
cis-retinoic acid. Systemic toxicity and therapeutic response were
evaluated in 30 patients with progressive metastatic renal cell
carcinoma. The results of this study are presented.
PATIENTS AND METHODS
The study protocol was approved by the Clinical Institutional
Ethical Review Board of the University of Hannover. Between
June 1998 and December 1998 we entered 30 patients in a phase II
clinical trial, (Table 1). All patients presented with histologically
confirmed metastatic renal cell carcinoma in advanced state, aged
18–75 years, expected survival of more than 3 months, Karnofsky
status of ≥ 70%, and signed informed consent.
Patients received the following capecitabine-based outpatient
chemo-immunotherapy regimen. Interferon-α was administered
subcutaneously at 5 MIU m–2 on day 1 of weeks 5–8. Interleukin-2
was administered subcutaneously at 10 MIU m–2 on days 3, 4 and
5 of weeks 1 and 4, and at 5 MIU m–2 on days 1, 3 and 5 of weeks
2 and 3. Capecitabine was administered orally on days 1–5 of
weeks 5–8 at 1000 mg m–2 twice daily. In addition, oral 13-cis-
retinoic acid was given at 34 mg m–2 daily during weeks 1–8.
Concomitant medication was given as needed to control adverse
effects of immunotherapy. Patients were treated on an outpatient
basis. Table 2 summarizes the therapy regimen used in this study.
8-week treatment cycles were repeated for up to three courses.
Number of treatment cycles varied exclusively based on progres-
sive disease of the patients. Re-evaluation of the patients’ tumour
status was performed between treatment cycles.
Response to therapy was evaluated according to World Health
Organization (WHO) criteria: complete response = disappearance
of all signs of disease for a minimum of 8 weeks; partial response
= 50% or more reduction in sum of products of the greatest
perpendicular diameters of measurable lesions, no increase in
lesion size and no new lesions; stable disease = less than a partial
response with no disease progression for at least 8 weeks; progres-
sive disease = 25% and more increase in sum of the products in the
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opment of new lesions.
Systemic toxicity was evaluated at weekly intervals using a
grading system adapted from the World Health Organization
(WHO).
Treatment efficacy was assessed on intent-to-treat basis.
RESULTS
Median follow-up and survival
Median follow-up of all patients is 8 months; except for three
patients, all patients are still alive.
Treatment response
Out of 30 patients, two (7%) achieved a complete response, and
eight (27%) had a partial remission (Table 3). The overall response
rate in this study was 34% (95% CI 17–53%). Complete responses
(CRs) occurred in lung (n = 1), liver (n = 1), pleura (n = 1) and
kidney (n = 1), while partial remissions (PRs) were seen in lung (n
= 4), liver (n = 3) (Figure 1), bone (n = 1), pleura (n = 1) and local
relapse (n = 1). The median response duration for CRs and PRs
were 9+ and 8+ months, respectively, with a range from 4–10+
months (Table 4). Except for one patient who developed brain
metastases, all patients are in sustained remission. In addition, 12
patients (40%) achieved stable disease upon chemo-
immunotherapy (median duration of 8+ months). Eight patients
(27%) had continued disease progression despite treatment.
Toxicity
In all patients, capecitabine therapy was completed without
modification of dosage or change of time-interval. 25 of 30
patients reported capecitabine-associated, mostly mild side-
effects (Table 5). No grade 4 toxicity was observed and only two
patients reported grade 3 malaise, one of them with concomitant
grade 3 nausea/vomiting and stomatitis. Grade 2 stomatitis,
dermatitis, hand-and-foot syndrome, anorexia, diarrhoea and
malaise were observed in four, two, two, two, one and one
patients, respectively. Mild grade 1 gastrointestinal side-effects
were reported in 16, and mild anorexia in nine patients with
moderate dermatitis, five showed early stages of hand-and-foot
syndrome in the upper extremity and/or nail disorders. Few
patients (n = 9) developed grade 1 neurological symptoms
including transient paraesthesiasis, headache and dizziness; eight
patients reported mild myalgia. Grade 1 neutropenia was seen in
one patient. No cardiac toxicity was noted; one patient with a
history of severe aortic stenosis tolerated capecitabine without
treatment-associated cardiac symptoms. In all patients treatment-
related toxicities resolved after cessation of therapy. No toxic
death occurred.
DISCUSSION
The use of biologic therapies has an established role in the treat-
ment of metastatic renal cell carcinoma (Quesada, 1988;
Belldegrun et al, 1991; Atzpodien et al, 1995a; Hofmockel et al,
1997). Potentially better results can be obtained using combination
therapies with cytokines and 5-fluorouracil (Lopez et al, 1996;
Hofmockel et al, 1997). Retinoids are known to control many
important biological processes, including differentation, morpho-
genesis, growth and tissue homeostasis (Warrel, 1994). Clinical
and pre-clinical results provide evidence for an antiproliferative
effect of 13-cis-retinoic acid in IFN-α -treated patients with renal
cell carcinoma (Buer et al, 1995; Motzer et al, 1995). Furthermore,
it seems to have a favourable effect in the treatment of renal
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Table 1 Patients characteristics
Characteristics Patients
Entered 30
Sex
male 24
female 6
Age (years)
median 60
range 38–73
Tumour nephrectomy
yes 29
no 1
Metastases
lung 23
bone 14
lymph nodes 12
liver 9
pleura 4
renal 4
adrenal gland 3
local relapse 1
othera 5
Prognosisb
good 5
poor 25
No. of treatment cycles 46 (range 1–3)
aTumour thrombus, soft tissue, pericardium, myelon (n = 2); bGood prognosis
was defined by the presence of lung metastases and the absence of bone
metastases, ESR < 70 mm after 1 h, serum lactic dehydrogenase < 280 units
l–1, neutrophilic granulocytes < 6000 µ l–1 and haemoglobin > 100 gm l–1 poor
prognosis patients included all others
Table 2 Home therapy regimen
Therapeutic agent Dose Regimen
Recombinant interferon-α 2 5 Million IU m–2 s.c. Once daily, day 1, weeks 1 and 4; days 1,3,5, week 2 and 3
10 Million IU m–2 s.c. Once daily, days 1,3,5, weeks 5–8
Recombinant interleukin-2 10 Million IU m–2 s.c. Twice daily, days 3,4,5, weeks 1 and 4
5 Million IU m–2 s.c. Once daily, days 1,3,5, weeks 2 and 3
Capecitabine 1000 mg m–2 p.o. Twice daily, days 1–5, weeks 5–8
13-cis-retinoic acid 35 mg m–2 p.o. Daily, days 1–7, weeks 1–8
Patients were entered between June 1998 and December 1998. Patients received cytokines and chemotherapy at home. Treatment cycles were repeated
every 2 months for an average of 1.5 cycles (range 1–3) unless disease progression occurredcancer, when added to immuno-chemotherapy regimens
(Atzpodien et al, 1995b).
Capecitabine, as a novel fluoropyrimidine carbamate which is
converted to 5-fluorouracil by three enzymes located in the liver
and in tumours, shows promising response rates and remission
durations while being very well tolerated in patients with metastatic
renal cell carcinoma. Due to four-fold higher thymidine phosphory-
lase (5-DFUR to 5-FU) activity in tumour compared to adjacent
healthy tissue (Frings, 1998), capecitabine allows for a more
specific anti-tumour therapy than conventional i.v. fluorouracil.
In the present home-therapy trial, we treated 30 patients with
progressive metastatic renal cell carcinoma with a combination of
p.o. capecitabine, s.c. IFN-α , s.c. IL-2 and 13-cis-RA. The dose of
capecitabine was adapted on an empirical basis from the recom-
mend dose (Roche Laboratories Inc, 1998). The continued admin-
istration over an extended treatment interval of 4 weeks in
combination with s.c. IFN-α , as opposed to an administration for 2
weeks followed by a 1-week rest period, required both a reduction
in the daily dose of capecitabine and a > 50% reduction in cumula-
tive 8-week capecitabine dosages. Capecitabine shows promising
objective response rates in various solid tumours (Frings, 1998).
We report first clinical results of capecitabine in the treatment of
advanced renal cancer.
Tumour regressions occurred in 34% of patients evaluated, with
7% CRs, and median response duration of 8+ months. These
results were comparable to other 5-FU-based therapy regimens in
renal cell carcinoma (Sella et al, 1994; Joffe et al, 1996;
Hofmockel et al, 1997; Tourani et al, 1998).
In the patients reported here, the rate of capecitabine-related
toxicity was low, and side-effects were moderate overall.
Predominant side-effects included gastrointestinal toxicities with
diarrhoea, nausea/vomiting, dyspepsia and stomatitis, and cuta-
neous symptoms including dermatitis and early stages of hand-
and-foot syndrome. A few patients experienced mild malaise and
mild neurological/musculoskeletal side-effects.
Capecitabine-associated systemic toxicities were mostly limited
to WHO grade 1, rarely grade 2. Only two patients experienced
WHO grade 3 effects. It should be noted that in addition to
capecitabine all patients were simultaneously treated with s.c.
IFN-α and p.o. 13-cis-RA.
This confirmed the excellent tolerability reported in other
malignancies at various dosages and treatment intervals of
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Table 3 Response to therapy
Tumour sitea Response
Complete Partial Stable Progressive Total
remission remission disease disease
Lung 1 6 10 6 23
Bone 1 3 7 3 14
Lymph nodes – 2 4 6 12
Liver – 4 2 3 9
Pleura 1 1 1 1 4
Kidney 1 – 1 2 4
Adrenal gland – – 2 1 3
Local relapse – 1 – – 1
Other – 1b 3c 1d 5
Patients 2 8 12 8 30
Riske Good/Poor 1/1 2/6 2/10 0/8 5/25
aPatients may have had more than one tumour site; bSoft tissue; ctumor thrombus, pericardium, myelon;
dmyelon; eGood Prognosis was defined by the presence of lung metastases and the absence of bone
metastases, ESR < 70 mm after 1 h, serum lactic dehydrogenase < 280 units l–1 neutrophilic granulocytes
< 6000 µ l–1 and haemoglobin > 100 gm l–1, poor prognosis patients included all others
Table 4 Remissions
Age Sex Interval between first Sites of metastatic Prognosisa Maximal response Remission duration Status
(years) diagnosis and appearance disease upon capecitabine, upon start to capecitabine, α INF, (months) from start
of metastases (months) α INF, IL2, 13-cis-RA of therapy IL2, 13-cis-RA of capecitabine,
α INF, IL2, 13-cis-RA
64 m 11 Lung Good CR 9+ alive
71 f 14 Kidney, pleura, bone Poor CR 9+ alive
41 f 0 Lung, lymph nodes, liver, bone Poor PR 4b alive
50 m 0 Lung Good PR 9+ alive
57 m 10 Lung, liver, local relapse Poor PR 8+ alive
57 m 25 Bone, soft tissue Poor PR 10+ alive
58 m 8 Liver, lymph nodes Poor PR 7+ alive
58 m 19 Lung, liver, pleura Good PR 8+ alive
64 m 23 Lung Poor PR 5+ alive
69 m 12 Lung, bone Poor PR 8+ alive
aGood prognosis was defined by the presence of lung metastases and the absence of bone metastases, ESR < 70 mm after 1 h, serum lactic dehydrogenase 
< 280 units l–1 neutrophilic granulocytes < 6000 µ l–1 and haemoglobin > 100 gm l–1, poor prognosis patients included all others; bThis patient developed brain
metastasescapecitabine (Budman et al, 1998; Mackean et al, 1998). Per oral
administration of capecitabine, in contrast to most chemothera-
peutic agents that are applied intravenously, allows treatment in an
outpatient or home therapy setting. This advantage will reduce
expenses and could enhance quality of life in the palliative setting.
Unless randomized data become available, the contribution of
capecitabine and its potential therapeutic feasibility cannot be
definitively assessed. Therefore, we have initiated a prospectively
controlled randomized clinical trial to investigate the role of
capecitabine in patients with advanced renal cell carcinoma.
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